Search Results - Dhiantravan, Nattakorn, MBBS

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Overall survival with [ 177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

    Overall survival with [ 177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 tr... by Hofman, Michael S, Prof, Emmett, Louise, Prof, Sandhu, Shahneen, MBBS, Iravani, Amir, MD, Buteau, James P, MD, Joshua, Anthony M, Prof, Goh, Jeffrey C, Prof, Pattison, David A, MBBS, Tan, Thean Hsiang, MBBS, Kirkwood, Ian D, MBBS, Ng, Siobhan, MBBS, Francis, Roslyn J, PhD, Gedye, Craig, PhD, Rutherford, Natalie K, MD, Weickhardt, Andrew, PhD, Scott, Andrew M, Prof, Lee, Sze-Ting, PhD, Kwan, Edmond M, PhD, Azad, Arun A, PhD, Ramdave, Shakher, MD, Redfern, Andrew D, MBChB, Macdonald, William, MPH, Guminski, Alex, PhD, Hsiao, Edward, MBChB, Chua, Wei, PhD, Lin, Peter, MBBS, Zhang, Alison Yan, PhD, Stockler, Martin R, Prof, Williams, Scott G, Prof, Martin, Andrew J, Prof, Davis, Ian D, Prof

    Published in The lancet oncology
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [ 177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

    PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [ 177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a bi... by Buteau, James P, MD, Martin, Andrew J, PhD, Emmett, Louise, Prof, Iravani, Amir, MD, Sandhu, Shahneen, MBBS, Joshua, Anthony M, Prof, Francis, Roslyn J, PhD, Zhang, Alison Y, PhD, Scott, Andrew M, Prof, Lee, Sze-Ting, PhD, Azad, Arun A, PhD, McJannett, Margaret M, Stockler, Martin R, Prof, Williams, Scott G, Prof, Davis, Ian D, Prof, Hofman, Michael S, Prof

    Published in The lancet oncology
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Sequential [ 177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

    Sequential [ 177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, ph... by Azad, Arun A, PhD, Bressel, Mathias, MSc, Tan, Hsiang, MBBS, Voskoboynik, Mark, MBBS, Suder, Aneta, MBChB, Weickhardt, Andrew J, DMedSc, Guminski, Alexander, PhD, Francis, Roslyn J, PhD, Saghebi, Javad, MBBS, Dhiantravan, Nattakorn, MBBS, Joshua, Anthony M, Prof, Emmett, Louise, Prof, Horvath, Lisa, Prof, Murphy, Declan G, Prof, Hsiao, Edward, MBChB, Balakrishnar, Bavanthi, MBBS, Lin, Peter, MBBS, Redfern, Andrew, MBChB, Macdonald, William, MBBS, Ng, Siobhan, MBBS, Lee, Sze-Ting, Prof, Pattison, David A, MBBS, Nadebaum, David, MBBS, Kirkwood, Ian D, MBBS, Hofman, Michael S, Prof

    Published in The lancet oncology
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:

Search Tools: